Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

1. Front Matter

   Pages i-xviii

   PDF

2. Physiology of erythropoiesis

   • Ugo Testa

   Pages 1-66

3. Biology of EPO and EPO-receptor

   • Catherine Lacombe, P. Mayeux

   Pages 67-80

4. The role of erythropoietin receptor expression on tumor cells

   • Joachim Fandrey

   Pages 81-102

5. Problems associated with erythropoietin receptor determination on tumor cells

   • Anders Österborg

   Pages 103-115

6. Definition, classification and characterization of anemia in cancer

   • M. R. Nowrousian

   Pages 117-148

7. Pathophysiology of anemia in cancer

   • M. R. Nowrousian

   Pages 149-188

8. Prevalence and incidence of anemia and risk factors for anemia in patients with cancer

   • Heinz Ludwig

   Pages 189-206

9. Significance of anemia in cancer chemotherapy

   • M. R. Nowrousian

   Pages 207-248

10. Incidence and impact of anemia in radiation oncology

    • Jürgen Dunst, M. Molls

    Pages 249-263

11. Relationship between hemoglobin levels and tumor oxygenation

    • Peter Vaupel, Arnulf Mayer, Michael Höckel

    Pages 265-282

12. Tumor hypoxia and therapeutic resistance

    • Peter Vaupel, Michael Höckel

    Pages 283-305

13. Symptoms of anemia

    • Robert Pirker

    Pages 307-315

14. Impact of anemia and red blood cell transfusion on organ function

    • M. R. Nowrousian

    Pages 317-367

15. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients

    • Zeeshan Butt, David Cella

    Pages 369-391

16. When to use red blood cell transfusions in cancer patients with solid tumours?

    • Jayin K. Jacob, Peter J. Barrett-Lee

    Pages 393-405

17. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations

    • Wolfgang Jelkmann

    Pages 407-431

18. Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma

    • Anders Österborg

    Pages 433-448

19. rhEPO in anemic patients with solid tumors and chemotherapy — efficacy and safety

    • M. R. Nowrousian

    Pages 449-508

20. Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia

    • Gary H. Lyman, John Glaspy

    Pages 509-530

Anemia is a frequent complication of cancer and its treatment. It produces many symptoms and significantly impairs metabolic and physiologic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. This book, now being published in its second edition, comprehensively presents the current knowledge on anemia in cancer and its treatment with rhEPO. Future developments are also discussed. Based on updated and new chapters, including a broader spectrum of topics, outstanding international experts describe the scientific and clinical aspects of anemia in various fields of oncology and give diagnostic and therapeutic recommendations on when and how to use rhEPO. The book, considered as a standard work, will again serve as an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.

• Fatigue
• Tumor
• anemia
• chemotherapy
• classification
• hemoglobin
• pathophysiology
• physiology
• radiation oncology
• therapeutic resistance
• transplantation
• Radiaton Oncology

• Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen, Essen, Germany

  Mohammad Resa Nowrousian

Policies and ethics